Oncology Mice Models Market Segmented By Humanized Immune System Mice Models, Syngeneic Tumor Mice Models, Immunodeficient Mice Models, NOG Mice Models, Spontaneous Tumor Mice Models Product
Industry: Healthcare
Published Date: April-2022
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 250
Report ID: PMRREP33046
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions & Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Success Factors
4.1. Oncology Drugs - Pipeline Analysis
4.1.1. By Intervention
4.1.2. By Phase
4.1.3. By Funding Authority
4.2. Immuno-Oncology Drugs - Pipeline Analysis
4.2.1. By Phase
4.2.2. By Funding Authority
4.3. List of Pharma Companies That Have Ongoing Immuno-Oncology Clinical Trials
4.4. List of Academic & Research Institutes Involved In Ongoing Immuno-Oncology Clinical Trials
4.5. List of Preclinical CROs
4.6. Parent Market Analysis
4.7. Relative Number of Combination Oncology Therapy Trials
4.8. Landscape of Immuno-Oncology Drug Development
4.9. List of Preclinical immuno-oncology models
4.9.1. Cell lines
4.9.2. Mice Models
4.9.3. Organoids/ spheroids
4.10. Key Regulatory Scenario
4.11. Porter’s Analysis
4.12. PESTLE Analysis
4.13. Supply Chain Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Expenditure
5.2. Forecast Factors - Relevance & Impact
5.2.1. Covid-19 Pandemic
5.2.2. Prevalence of cancer
5.2.3. Rise in R&D investments
5.2.4. Stringent Regulations
5.2.5. Rise in number of pre-clinical and clinical studies
5.2.6. Increasing investment in Cancer research
5.2.7. GDP Growth
5.2.8. Advancements in Models
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID19 Crisis Analysis
6.1. Current COVID19 Statistics and Probable Future Impact
6.2. Current GDP Projection and Probable Impact
6.3. Current Economic Projection as compared to 2008 Economic analysis
6.4. COVID19 and Impact Analysis
6.5. Recovery Scenario - Short term, Midterm, and Long Term Impact
7. Global Oncology Mice Models Market Demand (in Value or Size in US$ Mn) Analysis 2017-2021 and Forecast, 2022-2032
7.1. Historical Market Value (US$ Mn) Analysis, 2017- 2021
7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Oncology Mice Models Market Analysis 2017-2021 and Forecast 2022-2032, by Product
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Product, 2017-2021
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2022-2032
8.3.1. Humanized Immune System Mice Models
8.3.2. Syngeneic Tumor Mice Models
8.3.3. Immunodeficient Mice Models
8.3.4. NOG Mice Models
8.3.5. Spontaneous Tumor Mice Models
8.3.6. Others
8.4. Market Attractiveness Analysis By Product
9. Global Oncology Mice Models Market Analysis 2017-2021 and Forecast 2022-2032, by End User
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By End User, 2017-2021
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2022-2032
9.3.1. Contract Research Organizations
9.3.2. Pharma and Biopharma Companies
9.3.3. Academic and Research Institutes
9.4. Market Attractiveness Analysis By Indication
10. Global Oncology Mice Models Market Analysis 2017-2021 and Forecast 2022-2032, by Region
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By Region, 2017-2021
10.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2022-2032
10.3.1. The North America
10.3.2. Latin America
10.3.3. Europe
10.3.4. Asia Pacific
10.3.5. Middle East and Africa (MEA)
10.4 Market Attractiveness Analysis
11. North America Oncology Mice Models Market Analysis 2017-2021 and Forecast 2022-2032
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021
11.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032
11.3.1. By Country
11.3.2. By Product
11.3.3. By End User
11.4. Market Attractiveness Analysis
11.5. Key Market Participants - Intensity Mapping
11.6. Drivers and Restraints - Impact Analysis
12. Latin America Oncology Mice Models Market Analysis 2017-2021 and Forecast 2022-2032
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021
12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032
12.3.1. By Country
12.3.2. By Product
12.3.3. By End User
12.4. Market Attractiveness Analysis
12.5. Key Market Participants - Intensity Mapping
12.6. Drivers and Restraints - Impact Analysis
13. Europe Oncology Mice Models Market Analysis 2017-2021 and Forecast 2022-2032
13.1. Introduction / Key Findings
13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021
13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032
13.3.1. By Country
13.3.2. By Product
13.3.3. By End User
13.4. Market Attractiveness Analysis
13.5. Key Market Participants - Intensity Mapping
13.6. Drivers and Restraints - Impact Analysis
14. Asia Pacific Oncology Mice Models Market Analysis 2017-2021 and Forecast 2022-2032
14.1. Introduction / Key Findings
14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021
14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032
14.3.1. By Country
14.3.2. By Product
14.3.3. By End User
14.4. Market Attractiveness Analysis
14.5. Key Market Participants - Intensity Mapping
14.6. Drivers and Restraints - Impact Analysis
15. Middle East and Africa (MEA) Oncology Mice Models Market Analysis 2017-2021 and Forecast 2022-2032
15.1. Introduction / Key Findings
15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017-2021
15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032
15.3.1. By Country
15.3.2. By Product
15.3.3. By End User
15.4. Market Attractiveness Analysis
15.5. Key Market Participants - Intensity Mapping
15.6. Drivers and Restraints - Impact Analysis
16. Country Level Medical Cart Market Analysis and Forecast 2022 & 2032
16.1. Introduction
16.1.1. Market Value Proportion Analysis
16.1.2. Global VS. Country Growth Comparison
16.2. U.S. Medical Cart Market Analysis
16.2.1. By Product
16.2.2. By End User
16.3. Canada Medical Cart Market Analysis
16.3.1. By Product
16.3.2. By End User
16.4. Brazil Medical Cart Market Analysis
16.4.1. By Product
16.4.2. By End User
16.5. Argentina Medical Cart Market Analysis
16.5.1. By Product
16.5.2. By End User
16.6. Mexico Medical Cart Market Analysis
16.6.1. By Product
16.6.2. By End User
16.7. Germany Medical Cart Market Analysis
16.7.1. By Product
16.7.2. By End User
16.8. Italy Medical Cart Market Analysis
16.8.1. By Product
16.8.2. By End User
16.9. France Medical Cart Market Analysis
16.9.1. By Product
16.9.2. By End User
16.10. U.K. Medical Cart Market Analysis
16.10.1. By Product
16.10.2. By End User
16.11. Spain Medical Cart Market Analysis
16.11.1. By Product
16.11.2. By End User
16.12. BENELUX Medical Cart Market Analysis
16.12.1. By Product
16.12.2. By End User
16.13. Russia Medical Cart Market Analysis
16.13.1. By Product
16.13.2. By End User
16.14. China Medical Cart Market Analysis
16.14.1. By Product
16.14.2. By End User
16.15. Japan Medical Cart Market Analysis
16.15.1. By Product
16.15.2. By End User
16.16. India Medical Cart Market Analysis
16.16.1. By Product
16.16.2. By End User
16.17. Australia and New Zealand Medical Cart Market Analysis
16.17.1. By Product
16.17.2. By End User
16.18. GCC Countries Medical Cart Market Analysis
16.18.1. By Product
16.18.2. By End User
16.19. South Africa Medical Cart Market Analysis
16.19.1. By Product
16.19.2. By End User
17. Market Structure Analysis
17.1. Market Analysis by Tier of Companies
17.2. Market Share Analysis of Top Players
18. Competition Analysis
18.1. Competition Benchmarking
18.2. Competition Dashboard
18.3. Competition Deep Dive
18.3.1. The Jackson Laboratory
18.3.1.1. Overview
18.3.1.2. Product Portfolio
18.3.1.3. Key Financials
18.3.1.4. SWOT Analysis
18.3.1.5. Sales Footprint
18.3.1.6. Strategy Overview
18.3.1.6.1. Marketing Strategy
18.3.1.6.2. Product Strategy
18.3.1.6.3. Channel Strategy
18.3.2. Taconic Biosciences
18.3.2.1. Overview
18.3.2.2. Product Portfolio
18.3.2.3. Key Financials
18.3.2.4. SWOT Analysis
18.3.2.5. Sales Footprint
18.3.2.6. Strategy Overview
18.3.2.6.1. Marketing Strategy
18.3.2.6.2. Product Strategy
18.3.2.6.3. Channel Strategy
18.3.3. Charles River Laboratories
18.3.3.1. Overview
18.3.3.2. Product Portfolio
18.3.3.3. Key Financials
18.3.3.4. SWOT Analysis
18.3.3.5. Sales Footprint
18.3.3.6. Strategy Overview
18.3.3.6.1. Marketing Strategy
18.3.3.6.2. Product Strategy
18.3.3.6.3. Channel Strategy
18.3.4. Shanghai Model Organisms Center Inc.
18.3.4.1. Overview
18.3.4.2. Product Portfolio
18.3.4.3. Key Financials
18.3.4.4. SWOT Analysis
18.3.4.5. Sales Footprint
18.3.4.6. Strategy Overview
18.3.4.6.1. Marketing Strategy
18.3.4.6.2. Product Strategy
18.3.4.6.3. Channel Strategy
18.3.5. Envigo
18.3.5.1. Overview
18.3.5.2. Product Portfolio
18.3.5.3. Key Financials
18.3.5.4. SWOT Analysis
18.3.5.5. Sales Footprint
18.3.5.6. Strategy Overview
18.3.5.6.1. Marketing Strategy
18.3.5.6.2. Product Strategy
18.3.5.6.3. Channel Strategy
18.3.6. Biocytogen
18.3.6.1. Overview
18.3.6.2. Product Portfolio
18.3.6.3. Key Financials
18.3.6.4. SWOT Analysis
18.3.6.5. Sales Footprint
18.3.6.6. Strategy Overview
18.3.6.6.1. Marketing Strategy
18.3.6.6.2. Product Strategy
18.3.6.6.3. Channel Strategy
18.3.7. Genoway
18.3.7.1. Overview
18.3.7.2. Product Portfolio
18.3.7.3. Key Financials
18.3.7.4. SWOT Analysis
18.3.7.5. Sales Footprint
18.3.7.6. Strategy Overview
18.3.7.6.1. Marketing Strategy
18.3.7.6.2. Product Strategy
18.3.7.6.3. Channel Strategy
18.3.8. Crown Bioscience Inc. (JSR Corporation).
18.3.8.1. Overview
18.3.8.2. Product Portfolio
18.3.8.3. Key Financials
18.3.8.4. SWOT Analysis
18.3.8.5. Sales Footprint
18.3.8.6. Strategy Overview
18.3.8.6.1. Marketing Strategy
18.3.8.6.2. Product Strategy
18.3.8.6.3. Channel Strategy
18.3.9. Cyagen
18.3.9.1. Overview
18.3.9.2. Product Portfolio
18.3.9.3. Key Financials
18.3.9.4. SWOT Analysis
18.3.9.5. Sales Footprint
18.3.9.6. Strategy Overview
18.3.9.6.1. Marketing Strategy
18.3.9.6.2. Product Strategy
18.3.9.6.3. Channel Strategy
18.3.10. Applied stem cells
18.3.10.1. Overview
18.3.10.2. Product Portfolio
18.3.10.3. Key Financials
18.3.10.4. SWOT Analysis
18.3.10.5. Sales Footprint
18.3.10.6. Strategy Overview
18.3.10.6.1. Marketing Strategy
18.3.10.6.2. Product Strategy
18.3.10.6.3. Channel Strategy
18.3.11. Ingenious Targeting Laboratory
18.3.11.1. Overview
18.3.11.2. Product Portfolio
18.3.11.3. Key Financials
18.3.11.4. SWOT Analysis
18.3.11.5. Sales Footprint
18.3.11.6. Strategy Overview
18.3.11.6.1. Marketing Strategy
18.3.11.6.2. Product Strategy
18.3.11.6.3. Channel Strategy
18.3.12. PolyGene - Transgenic mice model company
18.3.12.1. Overview
18.3.12.2. Product Portfolio
18.3.12.3. Key Financials
18.3.12.4. SWOT Analysis
18.3.12.5. Sales Footprint
18.3.12.6. Strategy Overview
18.3.12.6.1. Marketing Strategy
18.3.12.6.2. Product Strategy
18.3.12.6.3. Channel Strategy
18.3.13. Creative Biolabs
18.3.13.1. Overview
18.3.13.2. Product Portfolio
18.3.13.3. Key Financials
18.3.13.4. SWOT Analysis
18.3.13.5. Sales Footprint
18.3.13.6. Strategy Overview
18.3.13.6.1. Marketing Strategy
18.3.13.6.2. Product Strategy
18.3.13.6.3. Channel Strategy
18.3.14. TransCure Bioservices
18.3.14.1. Overview
18.3.14.2. Product Portfolio
18.3.14.3. Key Financials
18.3.14.4. SWOT Analysis
18.3.14.5. Sales Footprint
18.3.14.6. Strategy Overview
18.3.14.6.1. Marketing Strategy
18.3.14.6.2. Product Strategy
18.3.14.6.3. Channel Strategy
18.3.15. Champions Oncology Inc
18.3.15.1. Overview
18.3.15.2. Product Portfolio
18.3.15.3. Key Financials
18.3.15.4. SWOT Analysis
18.3.15.5. Sales Footprint
18.3.15.6. Strategy Overview
18.3.15.6.1. Marketing Strategy
18.3.15.6.2. Product Strategy
18.3.15.6.3. Channel Strategy
18.3.16. Certis Oncology
18.3.16.1. Overview
18.3.16.2. Product Portfolio
18.3.16.3. Key Financials
18.3.16.4. SWOT Analysis
18.3.16.5. Sales Footprint
18.3.16.6. Strategy Overview
18.3.16.6.1. Marketing Strategy
18.3.16.6.2. Product Strategy
18.3.16.6.3. Channel Strategy
18.3.17. Signature
18.3.17.1. Overview
18.3.17.2. Product Portfolio
18.3.17.3. Key Financials
18.3.17.4. SWOT Analysis
18.3.17.5. Sales Footprint
18.3.17.6. Strategy Overview
18.3.17.6.1. Marketing Strategy
18.3.17.6.2. Product Strategy
18.3.17.6.3. Channel Strategy
18.3.18. Pharmaron
18.3.18.1. Overview
18.3.18.2. Product Portfolio
18.3.18.3. Key Financials
18.3.18.4. SWOT Analysis
18.3.18.5. Sales Footprint
18.3.18.6. Strategy Overview
18.3.18.6.1. Marketing Strategy
18.3.18.6.2. Product Strategy
18.3.18.6.3. Channel Strategy
18.3.19. Laboratory Corporation of America Holdings
18.3.19.1. Overview
18.3.19.2. Product Portfolio
18.3.19.3. Key Financials
18.3.19.4. SWOT Analysis
18.3.19.5. Sales Footprint
18.3.19.6. Strategy Overview
18.3.19.6.1. Marketing Strategy
18.3.19.6.2. Product Strategy
18.3.19.6.3. Channel Strategy
18.3.20. Gempharmatech
18.3.20.1. Overview
18.3.20.2. Product Portfolio
18.3.20.3. Key Financials
18.3.20.4. SWOT Analysis
18.3.20.5. Sales Footprint
18.3.20.6. Strategy Overview
18.3.20.6.1. Marketing Strategy
18.3.20.6.2. Product Strategy
18.3.20.6.3. Channel Strategy
18.3.21. Janvier Labs
18.3.21.1. Overview
18.3.21.2. Product Portfolio
18.3.21.3. Key Financials
18.3.21.4. SWOT Analysis
18.3.21.5. Sales Footprint
18.3.21.6. Strategy Overview
18.3.21.6.1. Marketing Strategy
18.3.21.6.2. Product Strategy
18.3.21.6.3. Channel Strategy
18.3.22. Harbour BioMed
18.3.22.1. Overview
18.3.22.2. Product Portfolio
18.3.22.3. Key Financials
18.3.22.4. SWOT Analysis
18.3.22.5. Sales Footprint
18.3.22.6. Strategy Overview
18.3.22.6.1. Marketing Strategy
18.3.22.6.2. Product Strategy
18.3.22.6.3. Channel Strategy
19. Assumptions and Acronyms Used
20. Research Methodology
Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
Table 01: Global Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Product
Table 02: Global Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by End User
Table 03: Global Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Region
Table 04: North America Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Product
Table 05: North America Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By End User
Table 06: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Product
Table 07: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By End User
Table 08: Europe Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Product
Table 09: Europe Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By End User
Table 10: Asia Pacific Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Product
Table 11: Asia Pacific Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By End User
Table 12: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, by Product
Table 13: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By End User
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized Version
Figure 01: Global Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017-2021
Figure 02: Global Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032
Figure 03: Global Oncology Mice Models Market Absolute $ Opportunity, 2022-2032
Figure 04: Global Oncology Mice Models Market Share Analysis (%) By Product, 2022 & 2032
Figure 05: Global Oncology Mice Models Market Y-o-Y Growth (%) By Product, 2022- 2032
Figure 06: Global Oncology Mice Models Market Attractiveness Analysis, By Product
Figure 07: Global Oncology Mice Models Market Share Analysis (%) By End User, 2022 & 2032
Figure 08: Global Oncology Mice Models Market Y-o-Y Growth (%) By End User, 2022-2032
Figure 09: Global Oncology Mice Models Market Attractiveness Analysis, By End User
Figure 10: Global Oncology Mice Models Market Share Analysis (%) By Region, 2022 & 2032
Figure 11: Global Oncology Mice Models Market Y-o-Y Growth (%) By Region, 2022-2032
Figure 12: Global Oncology Mice Models Market Attractiveness Analysis, By Region
Figure 13: North America Oncology Mice Models Market Value (US$ Mn) Analysis, 2021 (A), 2026 (F) & 2032 (F)
Figure 14: North America Oncology Mice Models Market Value (US$ Mn) Analysis, by Product, 2022
Figure 15: North America Oncology Mice Models Market Value (US$ Mn) Analysis, by End User, 2022
Figure 16: North America Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017-2021
Figure 17: North America Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032
Figure 18: North America Oncology Mice Models Market Attractiveness Analysis, By Product
Figure 19: North America Oncology Mice Models Market Attractiveness Analysis, By End User
Figure 20: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis, 2021 (A), 2026 (F) & 2032 (F)
Figure 21: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis, by Product, 2022
Figure 22: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis, by End User, 2022
Figure 23: Latin America Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017-2021
Figure 24: Latin America Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032
Figure 25: Latin America Oncology Mice Models Market Attractiveness Analysis, By Product
Figure 26: Latin America Oncology Mice Models Market Attractiveness Analysis, By End User
Figure 27: Europe Oncology Mice Models Market Value (US$ Mn) Analysis, 2021 (A), 2026 (F) & 2032 (F)
Figure 28: Europe Oncology Mice Models Market Value (US$ Mn) Analysis, by Product, 2022
Figure 29: Europe Oncology Mice Models Market Value (US$ Mn) Analysis, by End User, 2022
Figure 30: Europe Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017-2021
Figure 31: Europe Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032
Figure 32: Europe Oncology Mice Models Market Attractiveness Analysis, By Product
Figure 33: Europe Oncology Mice Models Market Attractiveness Analysis, By End User
Figure 35: Asia Pacific Oncology Mice Models Market Value (US$ Mn) Analysis, by Product, 2022
Figure 36: Asia Pacific Oncology Mice Models Market Value (US$ Mn) Analysis, by End User, 2022
Figure 37: Asia Pacific Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017-2021
Figure 38: Asia Pacific Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032
Figure 39: Asia Pacific Oncology Mice Models Market Attractiveness Analysis, By Product
Figure 40: Asia Pacific Oncology Mice Models Market Attractiveness Analysis, By End User
Figure 41: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis, 2021 (A), 2026 (F) & 2032 (F)
Figure 42: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis, by Product, 2022
Figure 43: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis, by End User, 2022
Figure 44: Middle East and Africa (MEA) Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017-2021
Figure 45: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032
Figure 46: Middle East and Africa (MEA) Oncology Mice Models Market Attractiveness Analysis, By Product
Figure 47: Middle East and Africa (MEA) Oncology Mice Models Market Attractiveness Analysis, By End User
Figure 48: U.S. Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
Figure 49: U.S. Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
Figure 50: Canada Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
Figure 51: Canada Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
Figure 52: Mexico Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
Figure 53: Mexico Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
Figure 54: Brazil Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
Figure 55: Brazil Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
Figure 56: India Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
Figure 57: India Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
Figure 58: China Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
Figure 59: China Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
Figure 60: Japan Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
Figure 61: Japan Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
Figure 62: Germany Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
Figure 63: Germany Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
Figure 64: France Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
Figure 65: France Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
Figure 66: Italy Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
Figure 67: Italy Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
Figure 68: Russia Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
Figure 69: Russia Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
Figure 70: GCC Countries Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
Figure 71: GCC Countries Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
Figure 72: South Africa Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032
Figure 73: South Africa Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032
